Literature DB >> 30488829

Objective and subjective assessment of xerostomia in patients of locally advanced head-and-neck cancers treated by intensity-modulated radiotherapy.

Punita Lal1, Vipul Nautiyal2, Mranalini Verma1, Rajan Yadav1, K J Maria Das1, Shaleen Kumar1.   

Abstract

BACKGROUND: Parotid-sparing intensity-modulated radiotherapy (IMRT) effectively reduces xerostomia in head-and-neck cancer (HNC). Changes in the salivary output at 1 year were studied and correlation with quality of life (QOL) changes in patients of locally advanced HNC (LAHNC) was drawn.
MATERIALS AND METHODS: Between October 2009 and October 2011, 20 patients of LAHNC were treated with IMRT using simultaneous integrated boost technique. High-risk clinical target volume (CTV) was given a dose of 66 Gy/30 fr, intermediate-risk CTV 60 Gy/30 fr, and low-risk CTV 54 Gy/30 fr. The saliva flow rate was estimated for 5 min at rest (unstimulated) and after using lemon drops (stimulated) for the next 5 min, at baseline (pretreatment), and 3, 6, and 12 months following treatment. Evaluation of patients' perception of dry mouth was done using EORTC-QLQ-C30 and HN35 questionnaires at the same time points.
RESULTS: Baseline unstimulated and stimulated salivary flow rates were 0.659 ml/min and 1.69 ml/min, respectively. At 3 months, a significant reduction in unstimulated (0.346 ml/min) and stimulated (0.80 ml/min) flow rate was observed. Unstimulated flow rate continued to decrease further till 6 months (0.295 ml/min), but slight improvement was seen in stimulated flow rate (0.91 ml/min). At 12 months, minimal recovery was observed in both unstimulated (0.362 ml/min) and stimulated flow rates (1.09 ml/min). EORTC-QOL questionnaire mean scores for dryness and stickiness of saliva were 10 and 15 at baseline and increased to 36 and 25, respectively, at 3 months. At 6 months, symptom score for dryness further increased to 45 and then decreased to 33 at 12 months. Stickiness score remained static from 3 to 12 months. Salivary flow rate correlated well with dry mouth (P < 0.05) but not with the perception of sticky saliva (P = 0.82) at 6 months and beyond.
CONCLUSIONS: Both salivary flow rate and xerostomia-related questions worsened at 3 months even with IMRT and showed a similar pattern of recovery.

Entities:  

Keywords:  Head-and-neck cancer; intensity-modulated radiotherapy; xerostomia

Mesh:

Year:  2018        PMID: 30488829     DOI: 10.4103/jcrt.JCRT_200_17

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  4 in total

1.  Quality of Life of Patients After Treatment for Cancer in the Head and Neck Region: A Case-Control Study.

Authors:  Rafael S Caetano; Fernando F Lima; Elâine P Gomes; Luiz E Volpato
Journal:  Cureus       Date:  2022-06-09

2.  Evaluation of the correlation between side effects to oral mucosa, salivary glands, and general health status with quality of life during intensity-modulated radiotherapy for head and neck cancer.

Authors:  Marina Kimie Oba; Lara Maria Alencar Ramos Innocentini; Gustavo Viani; Hilton Marcos Alves Ricz; Thiago de Carvalho Reis; Tatiane Cristina Ferrari; Leandro Dorigan de Macedo
Journal:  Support Care Cancer       Date:  2020-04-21       Impact factor: 3.603

3.  Early mortality after diagnosis of cancer of the head and neck - A population-based nationwide study.

Authors:  Charbél Talani; Antti Mäkitie; Martin Beran; Erik Holmberg; Göran Laurell; Lovisa Farnebo
Journal:  PLoS One       Date:  2019-10-02       Impact factor: 3.240

4.  The relationship between TNF-α gene promoter polymorphism (- 1211 T > C), the plasma concentration of TNF-α, and risk of oral mucositis and shortening of overall survival in patients subjected to intensity-modulated radiation therapy due to head and neck cancer.

Authors:  Radosław Mlak; Tomasz Powrózek; Anna Brzozowska; Iwona Homa-Mlak; Marcin Mazurek; Paweł Gołębiowski; Grzegorz Sobieszek; Teresa Małecka-Massalska
Journal:  Support Care Cancer       Date:  2019-05-10       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.